Here to stay schreef op 25 maart 2021 11:29:
Kan niet beoordelen in hoeverre deze mail echt is op dit moment maar de 'poster' is wel serieus.
Reminder -
31.01.2021 - Poster RBMInvest posted a 'response he received from GM' re End of year update (29.01.2021)
and 17% share drop, reproduced below:
++++
Hi R
Thank you for your email below and I certainly recognise some of the monikers at the bottom of your email although I try to refrain from reading the forums these days.
Novacyt has come (very quickly) from humble beginnings and as CEO I have tried to position the business in very difficult times to focus on delivery, not on hype. We continue to do this and we are building the foundations for a significant diagnostics business by ensuring we deliver performance, create expectations that can be realised and not to ramp the business. I know many companies that may have a different philosophy but in my experience hype without substance will always end up in misery.
I understand completely the balance between regulatory reporting and the PR for investors. We will never satisfy the latter but I can assure you we will always comply with the former.
The RNS Friday was a Trading Update. It was not meant to provide an operational review and certainly is not the platform to discuss future strategy. When we are ready to reveal this we will do so along with the usual R&D updates, product launches and other significant news.
However, at the end of the day with a 17% drop in SP despite our FY2020 performance means something can certainly be improved. However, it is not just a question of communication/PR. The issue is how to reconcile protecting its competitive position whilst trying to satisfy a largely retail shareholder base some of whom are watching daily, hourly movements in share price across two trading platforms. An interesting challenge and one that is not easily resolved. Can we improve communications? Yes and we will do so in time but not without ensuring the business continues to delivers first.
Believe me the constraints we operate under particularly on AIM are frustrating at times. Whilst IMO our position on comms remains the right one from many different perspectives I totally understand this does not help us whilst we have such a large disparate group of shareholders and we continue to trade on junior platforms. That said, we may not always have this balance right and you can be assured as we grow there will be more resource ploughed into communications/PR but actually marketing as a whole.
Nobody knows how long the current window of opportunity will stay open for but my personal focus is to maximize this to the benefit of the Company today so we can build the foundations to deliver a post-COVID exciting diagnostics company. When we are ready this will be revealed including our organic and inorganic investment plans.
I take your feedback constructively and with sympathy to the concerns.
I really appreciate the support Novacyt receives and with this support we will continue to try to do the right thing during our growth journey.
Thanks again,
Gra